Quick Answer
Petros Pharmaceuticals, Inc. reported Cash and Equivalents of $3.71 million for fiscal year 2024.
Petros Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $3.71M | -72.2% |
| 2023 | $13.34M | +41.5% |
| 2022 | $9.43M | -60.5% |
| 2021 | $23.85M | +39.1% |
| 2020 | $17.14M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.07M | — | -17.1% |
| June 30, 2025 | $7.32M | — | -18.0% |
| March 31, 2025 | $8.93M | — | +419.7% |
| December 31, 2024 | $1.72M | — | -87.1% |
| June 30, 2022 | $13.30M | +20.5% | -24.8% |
| March 31, 2022 | $17.67M | +21.3% | -25.9% |
| December 31, 2021 | $23.85M | +39.1% | +193.1% |
| September 30, 2021 | $8.14M | — | -26.3% |
- Petros Pharmaceuticals, Inc. showed a decrease of -72.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2024 period, Petros Pharmaceuticals, Inc.’s cash and equivalents has declined by 78.4% (from $17.14 million to $3.71 million).
- The most recent figure is from Petros Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: